News
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.
Pharmaceutical Technology on MSN2d
Insmed wins FDA approval for future blockbuster Brinsupri
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
Investor's Business Daily on MSN3d
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback